Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery,...
Read MorePosted by Samantha Budd | Dec 20, 2022 | Articles, News |
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery,...
Read MorePosted by Samantha Budd | Dec 19, 2022 | Eyewear
Posted by Samantha Budd | Dec 19, 2022 | Articles, News |
Spark™ 4, Shamir’s newest ultra-precise digital measurement device, deploys...
Read MorePosted by Samantha Budd | Dec 18, 2022 | Articles, News |
Standard of Care Rests on the Three Pillars of Mitigation, Measurement, and Management The...
Read MorePosted by Samantha Budd | Dec 18, 2022 | Articles, News |
Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on...
Read More